Literature DB >> 6151507

Dose-response relationship in normal subjects of prenalterol, a beta-adrenergic agonist with positive inotropic and resistance lowering effects.

S Rasmussen, P F Høilund-Carlsen, B Hesse, O J Hartling, J Fabricius, H Dige-Petersen, J Giese.   

Abstract

The acute haemodynamic effects of increasing doses of parenterally administered prenalterol-a beta-adrenergic stimulating drug-were assessed in normal subjects by means of radionuclide ventriculography. Prenalterol induced dose-related increases in the left ventricular ejection fraction and the systolic pressure end-systolic volume ratio. Left ventricular end-systolic and end-diastolic volumes decreased to the same extent accounting for an unchanged stroke volume. Cardiac output increased due to a rise in the heart rate. Systolic blood pressure increased, whereas diastolic and mean blood pressure remained unchanged. Calculated total peripheral resistance decreased significantly. The maximum effect of prenalterol on cardiac performance occurred with a dose of 18 to 36 micrograms/kg. Plasma concentrations of prenalterol showed large interindividual variations. In conclusion, prenalterol improves the pump function of the normal heart and causes a fall in peripheral vascular resistance, implying a reduction of the load on the heart. These effects may prove beneficial in the treatment of acute heart failure.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6151507     DOI: 10.1007/BF00556889

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  33 in total

1.  In vitro studies on the cardiac activity of prenalterol with reference to use in congestive heart failure.

Authors:  T P Kenakin; D Beek
Journal:  J Pharmacol Exp Ther       Date:  1982-01       Impact factor: 4.030

2.  Haemodynamic effects of prenalterol in patients with coronary heart disease.

Authors:  I Hutton; R G Murray; R N Boyes; A P Rae; W S Hillis
Journal:  Br Heart J       Date:  1980-02

3.  [Is the quotient: systolic peak pressure/end-systolic volume a useful parameter in the assessment of left ventricular function?].

Authors:  H C Mehmel; F Schwarz; J Manthey; G Schuler; H Tillmanns; W Kübler
Journal:  Z Kardiol       Date:  1984-04

4.  The effects of isoprenaline, atropine and dobutamine on ventricular volume curves obtained by radionuclide ventriculography.

Authors:  A L Muir; W J Hannan; R P Sapru; A K Boardman; P K Wraith; H M Brash
Journal:  Clin Sci (Lond)       Date:  1980-05       Impact factor: 6.124

5.  Effects of prenalterol in congestive heart failure.

Authors:  A Hjalmarson; N Abelardo; E Waagstein
Journal:  Eur Heart J       Date:  1982-12       Impact factor: 29.983

6.  Cardiovascular effects of prenalterol (H133/22) in normal man.

Authors:  D H Scott; G R Arthur; R N Boyes; D B Scott
Journal:  Br J Clin Pharmacol       Date:  1979-04       Impact factor: 4.335

7.  Effects of prenalterol on cardiac performance and transmural myocardial perfusion in patients with chronic renal failure.

Authors:  T Pedersen; K Cleemann-Rasmussen; I Brynjolf; H Ording; P E Nielsen; K Rasmussen
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Hemodynamic effects of intravenous prenalterol in severe heart failure.

Authors:  P C Kirlin; B Pitt
Journal:  Am J Cardiol       Date:  1981-03       Impact factor: 2.778

9.  Immediate haemodynamic effects of prenalterol, a new adrenergic beta-1-receptor agonist, in healthy volunteers.

Authors:  T L Svendsen; O J Hartling; J Trap-Jensen
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

10.  Contractile state of the left ventricle in man as evaluated from end-systolic pressure-volume relations.

Authors:  W Grossman; E Braunwald; T Mann; L P McLaurin; L H Green
Journal:  Circulation       Date:  1977-11       Impact factor: 29.690

View more
  1 in total

1.  An assessment of the partial agonist activity of Ro 31-1118, flusoxolol and pindolol in man.

Authors:  P M McCaffrey; J G Riddell; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.